Severe COVID-19 patients exhibit an ILC2 NKG2D⁺ population in their impaired ILC compartment

Affiliations

• ¹ Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland, and Ludwig Institute for Cancer Research, Lausanne, Switzerland.
• ² University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.
• ³ Department of Pharmacy, University Hospital of Besançon, F-25000, Besançon, France.
• ⁴ Department of Infectious Disease, University Hospital of Besançon, F-25000, Besançon, France.
• ⁵ UMR-CNRS 6249 Chrono-Environment, Université Bourgogne Franche-Comté, F-25000, Besançon, France.
• ⁶ Department of Oncology, UNIL-CHUV, University of Lausanne, 1066, Epalinges, Switzerland.
• ⁷ Department of Medical Oncology, University Hospital of Besançon, F-25000, Besançon, France.
• ⁸ Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland, and Ludwig Institute for Cancer Research, Lausanne, Switzerland. [email protected].